Synergistic Inhibition of Both P2Y 1 and P2Y 12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis | Zendy

Thomas Gremmel | Zendy; Ivan B. Yanachkov | Zendy; Milka Yanachkova | Zendy; George E. Wright | Zendy; Joseph M. Wider | Zendy; Vishnu Undyala | Zendy; Alan D. Michelson | Zendy; Andrew L. Frelinger | Zendy; Karin Przyklenk | Zendy

Open Access

Synergistic Inhibition of Both P2Y ₁ and P2Y ₁₂ Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis

Author(s) -

Thomas Gremmel,

Ivan B. Yanachkov,

Milka Yanachkova,

George E. Wright,

Joseph M. Wider,

Vishnu Undyala,

Alan D. Michelson,

Andrew L. Frelinger,

Karin Przyklenk

Publication year - 2016

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306885

Subject(s) - p2y12 , adenosine diphosphate , cangrelor , platelet , pharmacology , antithrombotic , adenosine , in vivo , p2y receptor , agonist , aspirin , purinergic receptor , platelet activation , bleeding time , chemistry , medicine , clopidogrel , receptor , biology , platelet aggregation , microbiology and biotechnology

Unlike currently approved adenosine diphosphate receptor antagonists, the new diadenosine tetraphosphate derivative GLS-409 targets not only P2Y12 but also the second human platelet adenosine diphosphate receptor P2Y1 and may, therefore, be a promising antiplatelet drug candidate. The current study is the first to investigate the in vivo antithrombotic effects of GLS-409.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research